Stocktoria
BICYCLE THERAPEUTICS PLC BCYC
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-05-23
BICYCLE THERAPEUTICS PLC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $72.6M | $35.3M | $27.0M | $14.5M | $11.7M |
| R&D expense | $240.3M | $173.0M | $156.5M | $81.6M | $44.9M |
| Operating income | -$247.1M | -$209.9M | -$189.9M | -$116.7M | -$65.6M |
| Interest expense | — | — | $3.3M | $3.3M | $3.0M |
| Income tax | $152,000 | -$4.8M | $1.5M | -$1.5M | -$1.7M |
| Net income | -$219.0M | -$169.0M | -$180.7M | -$112.7M | -$66.8M |
| EPS (diluted) | $-3.16 | $-2.90 | $-5.08 | $-3.80 | $-2.67 |
| Operating cash flow | -$249.7M | -$164.7M | -$60.6M | -$86.1M | -$14.8M |
| Free cash flow | -$252.0M | -$166.0M | -$63.6M | -$105.1M | -$16.8M |
| Cash & equivalents | $628.1M | $879.5M | $526.4M | $339.2M | $438.7M |
| Total assets | $717.6M | $956.9M | $595.3M | $410.6M | $479.8M |
| Total liabilities | $107.6M | $163.8M | $224.4M | $139.8M | $133.5M |
| Shareholders' equity | $610.0M | $793.1M | $370.9M | $270.8M | $346.3M |
Source: SEC EDGAR filings · CIK 0001761612 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.